developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagsclinical trials

#clinical trials

All articles tagged with "clinical trials"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca's Oral GLP-1 Pill Shows Promise in Mid-Stage Obesity and Diabetes Trials

AstraZeneca's oral GLP-1 pill showed 12% average weight loss in Phase 2 obesity trial.
Diabetes patients achieved significant HbA1c reductions with the once-daily pill.
Safety profile consistent with GLP-1 class; GI side effects mild to moderate.
Analysts say it's too early to compare with Novo Nordisk's Rybelsus or Lilly's orforglipron.

DE

DT Editorial Team·Jun 9, 2026·via statnews.com

More in Health→

Phase 3 trial links survodutide to liver fat and weight reductions in at-risk MASLD

Phase 3 trial links survodutide to liver fat and weight reductions in at-risk MASLD

Phase 3 SYNCHRONIZE-MASLD enrolled 216 adults with obesity and at-risk MASLD.
Both co-primary endpoints were met at week 48: liver fat reduction and weight loss.
Gastrointestinal side effects were most common and generally mild to moderate.

DE

DT Editorial Team·Jun 8, 2026·via nature.com

More in Health→

Kidney drug finerenone may help millions more patients after three major studies

Finerenone studies widen the case for kidney disease use

Three studies suggest finerenone may help beyond diabetic kidney disease.
FIND-CKD reported slower kidney decline and fewer major kidney and heart outcomes.
A glomerular disease analysis showed reduced progression risk and lower albuminuria.
The results could support broader future use if regulators and guidelines follow.

DE

DT Editorial Team·Jun 5, 2026·via medicalxpress.com

More in Health→

Menta

Experimental pancreatic cancer pill shows major survival gain

Daraxonrasib was tested in 500 patients with metastatic pancreatic cancer.
Researchers reported average survival of 13.2 months versus 6.7 months on chemotherapy.
The daily pill was also described as causing fewer side effects than standard chemotherapy.

DE

DT Editorial Team·Jun 2, 2026·via newscientist.com

More in Science→

Phase 1 trial points to early promise for IMA401 in solid tumors

Phase 1 trial points to early promise for IMA401 in solid tumors

IMA401 was tested in 61 patients with advanced solid tumors.
The maximum tolerated dose was not reached under the trial protocol.
Researchers set a recommended phase 2 dose of 1 mg to 2 mg every two weeks.
Common treatment-related side effects included low-grade cytokine release syndrome, lymphopenia, and neutropenia.

DE

DT Editorial Team·Jun 1, 2026·via nature.com

DE

DT Editorial Team·May 31, 2026·via medicalxpress.com

DE

DT Editorial Team·May 29, 2026·via medicalxpress.com

DE

DT Editorial Team·May 25, 2026·via statnews.com

DE

DT Editorial Team·May 24, 2026·via endpoints.news

DE

DT Editorial Team·May 13, 2026·via nature.com

DE

DT Editorial Team·May 12, 2026·via nature.com

DE

DT Editorial Team·May 11, 2026·via endpoints.news

DE

DT Editorial Team·May 6, 2026·via medicalxpress.com

DE

DT Editorial Team·May 4, 2026·via medicalxpress.com

DE

DT Editorial Team·May 2, 2026·via endpoints.news

DE

DT Editorial Team·Apr 29, 2026·via statnews.com

DE

DT Editorial Team·Apr 28, 2026·via endpoints.news

DE

DT Editorial Team·Apr 28, 2026·via endpoints.news

DE

DT Editorial Team·Apr 28, 2026·via nature.com

DE

DT Editorial Team·Apr 27, 2026·via medicalxpress.com

1
2
Next

More in Health→

One-time gene editing treatment lowers 'bad' cholesterol by up to 62%

One-Shot Gene Editing Therapy Cuts LDL Cholesterol in Early Trial

A Phase 1b study tested VERVE-102 in 35 adults with inherited high cholesterol or early coronary artery disease.
At the highest dose, LDL cholesterol fell by up to 62% after a single infusion.
The therapy works by switching off the PCSK9 pathway in the liver, aiming for a durable one-time effect.

More in Health→

One in five patients achieve functional hepatitis B cure after 24 weeks of bepirovirsen

Bepirovirsen posts phase III gains in hepatitis B cure push

Two duplicate phase III trials reported functional cure rates of 20% and 19%.
No patients in the placebo groups achieved a functional cure.
About 24% of treated patients were able to discontinue nucleoside analog therapy.

More in Health→

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

Eli Lilly Says Verve Gene-Editing Therapy Cut Cholesterol in Early Trial

Lilly says a high dose of VERVE-102 reduced cholesterol by 62% in an early study.
The result points to early biological activity for a gene-editing therapy.
Key questions on safety, durability, and larger-trial performance remain open.

More in Health→

Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Biogen and Denali Pull Back a Parkinson’s Program After a Mid-Stage Failure

Biogen and Denali’s LRRK2 inhibitor failed a Phase 2b study in early Parkinson’s disease.
The companies are dropping the program in certain patients with non-genetic Parkinson’s.
The supplied source text does not provide detailed study data, but it clearly establishes a strategic pullback.

More in Health→

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine

Oral GLP-1 candidate helps patients hold onto weight loss after injectable therapy

Phase 3b data showed oral orforglipron preserved more prior weight loss than placebo after injectable therapy.
Benefits were seen in participants previously treated with either tirzepatide or semaglutide.
The study supports an oral maintenance strategy but did not compare switching with staying on injectables.

More in Health→

Low-Dose Digoxin Misses Primary Goal but Hints at Fewer Heart Failure Events

The DECISION trial randomized 1,001 heart failure patients to low-dose digoxin or placebo.
The primary composite outcome was not significantly reduced in the digoxin group.
Worsening heart failure events were numerically lower with digoxin, suggesting a possible signal short of statistical significance.

More in Health→

EnGene

EnGene Selloff Puts Fresh Pressure on Bladder Cancer Program

Updated pivotal Phase 2 bladder cancer data triggered a sharp negative market reaction for EnGene.
The source says investors were alarmed and the therapy’s future prospects came under new pressure.
The episode underscores how quickly biotech valuations can move on revised clinical data.

More in Health→

Alzheimer’s Drug Pipeline Expands Beyond Amyloid as Trials Surge

An annual report found a 35% rise in Alzheimer’s clinical trials and a 40% increase in therapies being tested since 2016.
Amyloid-targeting drugs now make up about 20% of the pipeline, down from roughly one-third in 2016.
Inflammation and immune-targeting therapies have grown to 18% of the pipeline, reflecting a broader scientific strategy.

More in Health→

Clinical trials are key to improving medicines access in Africa (via weforum.org)

Why Africa’s Absence From Clinical Trials Matters Far Beyond Research Design

The candidate argues that Africa is missing from too much of the clinical trial system.
That underrepresentation is notable because the continent carries a large disease burden.
The gap challenges the idea that modern medical evidence is fully universal.
The issue has implications for both research quality and health equity.

More in Health→

Summit slips on ivonescimab

Summit Therapeutics Drops After Apparent Phase 3 Miss Revives the Market’s Biotech Patience Problem

Summit Therapeutics shares fell nearly 20% after the close on May 1, 2026.
The trigger was described as an apparent statistical miss in part of a Phase 3 trial for ivonescimab.
The move reflects how sharply biotech investors now react to ambiguous late-stage data.

More in Health→

FDA launches effort to speed up clinical trials, using AI

FDA Pushes Real-Time, AI-Assisted Trial Oversight in Bid to Speed Drug Development

Candidate metadata says the FDA is launching an effort to speed up clinical trials using AI.
The supplied excerpt says real-time monitoring may shorten the interval between trial phases.
The initiative points to a regulatory shift toward more continuous oversight of clinical data.

More in Health→

FDA announces real-time clinical trial data effort, with AstraZeneca and Amgen as test cases

FDA Tests a New Regulatory Model With Real-Time Clinical Trial Data

The FDA is launching a pilot to collect and review clinical trial data in real time.
AstraZeneca and Amgen are the first companies participating in the program.
The effort could shift regulatory review toward earlier and more continuous oversight of ongoing studies.

More in Health→

Intellia

Intellia’s Phase 3 Result Marks a Turning Point for In Vivo CRISPR Medicine

Intellia’s in vivo CRISPR therapy reportedly succeeded in a Phase 3 trial.
The result is described as a first for an in vivo CRISPR treatment.
The milestone could put the therapy on track for potential FDA approval.
The outcome is significant for the broader field of gene editing delivered directly inside the body.

More in Health→

Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial - Nature Medicine

Pilot treatment targeting a key preeclampsia protein shows early safety signal in very preterm pregnancies

Pilot study tested selective removal of sFlt-1, a protein implicated in preeclampsia.
Researchers reported stable maternal and fetal measures during treatment in the study setting.
Multiple-dose treatment was associated with modest average reductions in sFlt-1 and mean arterial pressure.
Larger controlled trials are needed to determine whether the approach improves pregnancy and neonatal outcomes.

More in Health→

Stable PSA Readings May Miss Prostate Cancer Progression, Trial Analysis Finds

A large analysis of two clinical trials found scans can detect progression despite stable biomarkers.
The finding applies to patients treated with androgen receptor pathway inhibitors.
The result suggests biomarker stability alone may not be enough to rule out advancing disease.

More in Health→